Long-term study of KarXT for agitation in Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished a prior KarXT study called CN012-0023 or CN012-0024.
- You need a caregiver who can spend about 8 hours a week with you.
- You should not have serious untreated health problems like heart, lung, or kidney disease that could make the study unsafe.
- Other standard study rules also apply.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
This study tests the long-term safety of KarXT for people with bipolar I disorder who are having a manic or mixed episode. It is for people who either completed a previous KarXT study or are new to the study and have moderate to severe mania symptoms.
Hear when a new Agitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.